Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Lilac Device Trial
NCT07142304 · View on ClinicalTrials.gov ↗
Study Summary
Chemotherapy drugs, used in the treatment of cancer, have the potential of inducing peripheral neuropathy (PN) as a side effect. This side effect is commonly referred to as CIPN, or chemotherapy-induced peripheral neuropathy. The Lilac Glove and Boot devices apply a low pressure across the surface of the hands and feet, respectively, to reduce access of chemotherapy to the peripheral nerves on the hands and feet. The small amount of pressure reduces the level of chemotherapy reaching the peripheral nerves, hence increasing the likelihood of nerve preservation during treatment and thus may potentially temporarily prevent the onset of moderate to severe PN symptoms induced by chemotherapy in the hands and feet while receiving treatment
Conditions Studied
Interventions
- DEVICE Sham device
- DEVICE The Lilac Device
Study Locations (8)
Ohio
- Springfield Regional Cancer Center — Springfield
- Mercy Health St. Elizabeth Hospital — Youngstown
California
- Palomar Medical Center Poway — Poway
Florida
- Hialeah Hospital — Hialeah
Hawaii
- Hawaii Cancer Care — Honolulu
Illinois
- Hope and Healing Cancer Services — Hinsdale
Minnesota
- Health Partners Frauenshuh Cancer Center — Minneapolis
Wisconsin
- Hospital Sisters Health System - St.Vincent & St.Mary's — Green Bay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2026-10 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07142304
The ClinicalTrials.gov registry entry for NCT07142304 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luminate Medical, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Chemotherapy Induced Peripheral Neuropathy (CIPN) appearing as the primary indexed condition, and to 2 interventions — of which Sham device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07142304 reports 8 study locations spanning 7 distinct geographic areas — top geographies include Ohio, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07142304 about?
NCT07142304 is a clinical study titled "The Lilac Device Trial". Chemotherapy drugs, used in the treatment of cancer, have the potential of inducing peripheral neuropathy (PN) as a side effect. This side effect is commonly referred to as CIPN, or chemotherapy-induced peripheral neuropathy. The Lilac Glove and Boot devices apply a low pressure across the surface ...
What is the current status of trial NCT07142304?
This trial is currently recruiting. It is a NA study. The enrollment target is 142 participants. The study started on 2025-10-03. Estimated completion is 2026-10.
What conditions does trial NCT07142304 study?
This clinical trial studies the following conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07142304?
The interventions under investigation include: Sham device (DEVICE), The Lilac Device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07142304?
This trial is sponsored by Luminate Medical, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07142304 being conducted?
This trial has 8 study locations across California, Florida, Hawaii, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.